These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21714780)

  • 1. Bayesian enrichment strategies for randomized discontinuation trials.
    Trippa L; Rosner GL; Müller P
    Biometrics; 2012 Mar; 68(1):203-11. PubMed ID: 21714780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discussion of the article by Trippa, Rosner, and Müller on Bayesian enrichment strategies for randomized discontinuation trials.
    Schmidli H; Neuenschwander B
    Biometrics; 2012 Mar; 68(1):212-4; discussion 224-5. PubMed ID: 21714781
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discussion: “Bayesian enrichment strategies for randomized discontinuation trials”.
    Perevozskaya I
    Biometrics; 2012 Mar; 68(1):217-8; discussion 224-5. PubMed ID: 21714783
    [No Abstract]   [Full Text] [Related]  

  • 4. Discussion of Trippa, Rosner, and Müller--Bayesian enrichment strategies for randomized discontinuation trials.
    Grieve AP
    Biometrics; 2012 Mar; 68(1):219-23; discussion 224-5. PubMed ID: 21714784
    [No Abstract]   [Full Text] [Related]  

  • 5. Optimal Bayesian enrichment: a view from the closet.
    Gönen M
    Biometrics; 2012 Mar; 68(1):215-6; discussion 224-5. PubMed ID: 21714782
    [No Abstract]   [Full Text] [Related]  

  • 6. Bayesian designs and the control of frequentist characteristics: a practical solution.
    Ventz S; Trippa L
    Biometrics; 2015 Mar; 71(1):218-226. PubMed ID: 25196832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using joint utilities of the times to response and toxicity to adaptively optimize schedule-dose regimes.
    Thall PF; Nguyen HQ; Braun TM; Qazilbash MH
    Biometrics; 2013 Sep; 69(3):673-82. PubMed ID: 23957592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials.
    Wijeysundera DN; Austin PC; Hux JE; Beattie WS; Laupacis A
    J Clin Epidemiol; 2009 Jan; 62(1):13-21.e5. PubMed ID: 18947971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using short-term response information to facilitate adaptive randomization for survival clinical trials.
    Huang X; Ning J; Li Y; Estey E; Issa JP; Berry DA
    Stat Med; 2009 May; 28(12):1680-9. PubMed ID: 19326367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.
    Barry WT; Perou CM; Marcom PK; Carey LA; Ibrahim JG
    J Biopharm Stat; 2015; 25(1):66-88. PubMed ID: 24836519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of single-arm vs. randomized phase II clinical trials: a Bayesian approach.
    Sambucini V
    J Biopharm Stat; 2015; 25(3):474-89. PubMed ID: 24896838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncertainty directed factorial clinical trials.
    Kotecha G; Ventz S; Fortini S; Trippa L
    Biostatistics; 2024 Jul; 25(3):833-851. PubMed ID: 38330084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized two-stage design for phase II clinical trials based on a Bayesian predictive approach.
    Cellamare M; Sambucini V
    Stat Med; 2015 Mar; 34(6):1059-78. PubMed ID: 25545805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response-adaptive randomization for multi-arm clinical trials using the forward looking Gittins index rule.
    Villar SS; Wason J; Bowden J
    Biometrics; 2015 Dec; 71(4):969-78. PubMed ID: 26098023
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bayesian optimal design for phase II screening trials.
    Ding M; Rosner GL; Müller P
    Biometrics; 2008 Sep; 64(3):886-894. PubMed ID: 18162113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A nonparametric Bayesian basket trial design.
    Xu Y; Müller P; Tsimberidou AM; Berry D
    Biom J; 2019 Sep; 61(5):1160-1174. PubMed ID: 29808479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Bayesian decision-theoretic sequential response-adaptive randomization design.
    Jiang F; Jack Lee J; Müller P
    Stat Med; 2013 May; 32(12):1975-94. PubMed ID: 23315678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal and repeated cross-sectional cluster-randomization designs using mixed effects regression for binary outcomes: bias and coverage of frequentist and Bayesian methods.
    Localio AR; Berlin JA; Have TR
    Stat Med; 2006 Aug; 25(16):2720-36. PubMed ID: 16345043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A semiparametric Bayesian approach to the random effects model.
    Kleinman KP; Ibrahim JG
    Biometrics; 1998 Sep; 54(3):921-38. PubMed ID: 9750242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation.
    Morita S; Yamamoto H; Sugitani Y
    Stat Med; 2014 Oct; 33(23):4008-16. PubMed ID: 24820639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.